重组人脑利钠肽用于重症急性心肌炎伴心力衰竭患者治疗的临床研究(1)
摘 要：目的 研究重组人脑利钠肽应用于重症急性心肌炎伴心力衰竭患者在临床治疗的效果。方法 选取我院2014年1月～2017年6月收治的98例急性心肌炎合并心力衰竭患者，并随机均分为实验组和对照组，每组49例。对照组行常规的抗心力衰竭治疗，实验组在对照组的基础上行静脉泵入重组人脑利钠肽。72 h后测定两组患者用药前后血清N末端脑钠肽前体水平、左室射血分数和Supper-Score的评分。结果 72 h后两组患者N末端脑钠肽前提水平均：用药前>对照组>实验组，左室射血分数：实验组>对照组>用药前，差异存在统计学意义(P<0.05)，两组患者用药前N末端脑钠肽前体水平、左室射血分数的差异，无统计学意义(P>0.05)。结论 重组人脑利钠肽应用于重症急性心肌炎伴心力衰竭患者的疗效显著，可推广应用。
关键词：重组人脑利钠肽；重症急性心肌炎；心力衰竭；
中图分类号：R542.21 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.08.042
, 百拇医药
文章编号：1006-1959(2018)08-0126-03
Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure
CHENG Lin
(Department of Heart，Subject One，Jiamusi Central Hospital，Jiamusi 154002，Heilongjiang，China)
Abstract：Objective To study the clinical efficacy of recombinant human brain natriuretic peptide in the treatment of severe acute myocarditis with heart failure.Methods 98 patients with acute myocarditis complicated with heart failure from January 2014 to June 2017 were randomly divided into experimental group and control group with 49 cases in each group.The control group was treated with routine anti-heart failure therapy，on the basis of the control group，the experimental group was injected with recombinant human brain natriuretic peptide.72 h on the basis of the control group.The serum N terminal brain natriuretic peptide level，the left ventricular ejection fraction and the score of Supper-Score were measured before and after the use of the two groups.Results After 72 h，the N terminal brain natriuretic peptide precondition water was mean：before medication>control group>experimental group，left ventricular ejection fraction：experimental group>control group>before medication，the difference was statistically significant(P<0.05).The difference of the level of brain natriuretic precursor and left ventricular ejection fraction in the two groups before use was not statistically significant(P>0.05).Conclusion Recombinant human brain natriuretic peptide is effective in the treatment of severe acute myocarditis with heart failure，and it can be widely applied.
, 百拇医药
Key words：Recombinant human brain natriuretic peptide；Severe acute myocarditis；Heart failure
心肌炎(myocarditis)是指各種原因引起的心肌的炎症性病变。根据资料显示，近年来居民病毒性心肌炎发病率呈逐年上升趋势，这之中有些患者的病情异常凶险，主要表现为心源性休克、心力衰竭和恶性心律失常等，临床上称为重症心肌炎，重症急性心肌炎严重威胁着居民的生命健康，不仅源于该疾病本身，还因为该疾病容易引起各类并发症，心力衰竭就是最常见的一类。对于急性重症心肌炎临床上没有确切有效的治疗方法。但是目前在治疗心力衰竭方面，最有效的方法就是重组人脑利钠肽，这也为治疗重症急性心肌炎提供了新的研究方向[1]。为了探究重组人脑利钠肽对重症急性心肌炎伴心力衰竭患者的效果与否，本研究随机选取我院98例重症急性心肌炎患者作为研究对象，探讨重组人脑利钠肽对重症急性心肌炎患者的治疗效果，现分析如下。, http://www.100md.com(程林)
关键词：重组人脑利钠肽；重症急性心肌炎；心力衰竭；
中图分类号：R542.21 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.08.042
, 百拇医药
文章编号：1006-1959(2018)08-0126-03
Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure
CHENG Lin
(Department of Heart，Subject One，Jiamusi Central Hospital，Jiamusi 154002，Heilongjiang，China)
Abstract：Objective To study the clinical efficacy of recombinant human brain natriuretic peptide in the treatment of severe acute myocarditis with heart failure.Methods 98 patients with acute myocarditis complicated with heart failure from January 2014 to June 2017 were randomly divided into experimental group and control group with 49 cases in each group.The control group was treated with routine anti-heart failure therapy，on the basis of the control group，the experimental group was injected with recombinant human brain natriuretic peptide.72 h on the basis of the control group.The serum N terminal brain natriuretic peptide level，the left ventricular ejection fraction and the score of Supper-Score were measured before and after the use of the two groups.Results After 72 h，the N terminal brain natriuretic peptide precondition water was mean：before medication>control group>experimental group，left ventricular ejection fraction：experimental group>control group>before medication，the difference was statistically significant(P<0.05).The difference of the level of brain natriuretic precursor and left ventricular ejection fraction in the two groups before use was not statistically significant(P>0.05).Conclusion Recombinant human brain natriuretic peptide is effective in the treatment of severe acute myocarditis with heart failure，and it can be widely applied.
, 百拇医药
Key words：Recombinant human brain natriuretic peptide；Severe acute myocarditis；Heart failure
心肌炎(myocarditis)是指各種原因引起的心肌的炎症性病变。根据资料显示，近年来居民病毒性心肌炎发病率呈逐年上升趋势，这之中有些患者的病情异常凶险，主要表现为心源性休克、心力衰竭和恶性心律失常等，临床上称为重症心肌炎，重症急性心肌炎严重威胁着居民的生命健康，不仅源于该疾病本身，还因为该疾病容易引起各类并发症，心力衰竭就是最常见的一类。对于急性重症心肌炎临床上没有确切有效的治疗方法。但是目前在治疗心力衰竭方面，最有效的方法就是重组人脑利钠肽，这也为治疗重症急性心肌炎提供了新的研究方向[1]。为了探究重组人脑利钠肽对重症急性心肌炎伴心力衰竭患者的效果与否，本研究随机选取我院98例重症急性心肌炎患者作为研究对象，探讨重组人脑利钠肽对重症急性心肌炎患者的治疗效果，现分析如下。, http://www.100md.com(程林)